Astec LifeSciences Limited — Updates, 23-04-2025: Press Release

Astec LifeSciences Limited reported its financial results for Q4 and the fiscal year ending March 31, 2025. Q4 FY25 saw consolidated total income of ₹120.3 crore, a decline from ₹155.8 crore in Q4 FY24, yet marking a 25.6% improvement from ₹95.8 crore in Q3 FY25. EBITDA for the quarter was ₹6.3 crore, down from ₹14.8 crore year-on-year but showing a sequential gain from a loss of ₹3.8 crore in Q3.

For the fiscal year FY24-25, consolidated total income amounted to ₹386.9 crore, down from ₹463.8 crore in FY23-24, with an EBITDA loss of ₹60.6 crore compared to a loss of ₹0.3 crore in the prior year. The Chairman noted a sequential improvement in performance due to increased volumes and prices in the Enterprise business. Despite a challenging year driven by lower CDMO volumes and declining prices, there’s an expectation for positive trends and gradual recovery in demand. Investors should watch closely for recovery signals in the coming year as the company strengthens its CDMO pipeline.